Large Granular Lymphocytes in mNSCLC Treated With Nivolumab
Trial Parameters
Brief Summary
Large granular lymphocytes (LGLs), which constitute 10-15% of peripheral blood mononuclear cells, are large lymphocytes with a round nucleus, large cytoplasm, and azurophilic granules in the cytoplasm. Most normal LGLs in peripheral blood are natural killer (NK) cells, but some are T lymphocytes. These cells cannot be measured by a standard complete blood count (CBC) test. These cells, which can be detected by peripheral smear, are expressed numerically and as a percentage relative to other cells. The aim of this study is to determine the relationship between the percentage of LGLs at baseline and at three months and the response and clinical parameters in participants with metastatic non-small cell lung cancer treated with nivolumab in second-line therapy.
Eligibility Criteria
Inclusion Criteria: * Histological and staging diagnosis of metastatic non-small cell lung cancer * ECOG performance score between 0 and 2 * No contraindications for nivolumab Exclusion Criteria: * Patients diagnosed with mNSCLC who received nivolumab as adjuvant or perioperative therapy * Those with a second primary malignancy undergoing active treatment * Those who have not signed the informed consent form * Those with additional hematological malignancies such as leukemia, lymphoma, or myelodysplastic syndrome * Those who have undergone palliative or curative radiotherapy within the last three months * Those with active viral/bacterial infections before nivolumab treatment * Patients who have used steroids in the last three months